Sri Gajanand Bio Product Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 10-12-2024
- Paid Up Capital ₹ 2.50 M
as on 10-12-2024
- Company Age 11 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.01 Cr
as on 10-12-2024
- Satisfied Charges ₹ 2.14 Cr
as on 10-12-2024
- Revenue 58.89%
(FY 2023)
- Profit 70.08%
(FY 2023)
- Ebitda 169.35%
(FY 2023)
- Net Worth -30.24%
(FY 2023)
- Total Assets -5.20%
(FY 2023)
About Sri Gajanand Bio Product
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹1.01 Cr. The company has closed loans amounting to ₹2.14 Cr, as per Ministry of Corporate Affairs (MCA) records.
Shilpa Tulsyan and Manju Tulsyan serve as directors at the Company.
- CIN/LLPIN
U01403JH2013PTC001137
- Company No.
001137
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Apr 2013
- Date of AGM
14 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jharkhand
Industry
Company Details
- Location
Ranchi, Jharkhand, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sri Gajanand Bio Product?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shilpa Tulsyan  | Director | 17-Apr-2013 | Current |
| Manju Tulsyan | Director | 17-Apr-2013 | Current |
Financial Performance of Sri Gajanand Bio Product.
Sri Gajanand Bio Product Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 58.89% increase. The company also saw a substantial improvement in profitability, with a 70.08% increase in profit. The company's net worth observed a substantial decline by a decrease of 30.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sri Gajanand Bio Product?
Unlock access to Sri Gajanand Bio Product's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 06 Nov 2021 | ₹1.01 Cr | Open |
Hdfc Bank Limited Creation Date: 23 Oct 2020 | ₹9.69 M | Satisfied |
Others Creation Date: 21 Oct 2016 | ₹1.17 Cr | Satisfied |
How Many Employees Work at Sri Gajanand Bio Product?
Sri Gajanand Bio Product has a workforce of 15 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sri Gajanand Bio Product, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sri Gajanand Bio Product's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
